Yazar "Bolaman, Z" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ X ]
    Öğe
    Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia
    (Saudi Med J, 2004) Ayyildiz, O; Isikdogan, A; Bolaman, Z; Muftuoglu, E
    [Abstract Not Available]
  • [ X ]
    Öğe
    The importance of CD7 and CD56 antigens in acute leukaemias
    (Wiley, 2004) Tiftik, N; Bolaman, Z; Batun, S; Ayyildiz, O; Isikdogan, A; Kadikoylu, G; Muftuoglu, E
    The prognostic significance of immunophenotypical properties of leukaemic cells is well known. However, the biological and clinical significance of CD7 and CD56 antigen expression in acute leukaemias are not clearly established. In patients with acute leukaemias, we identified CD7 and CD56 expression and analysed their associations with markers expressed early in haemopoietic ontogeny and clinical parameters. Among 22 patients with acute leukaemia [12 acute myeloblastic leukaemia (AML), 10 acute lymphoblastic leukaemia (ALL)], we found CD7 positivity in 15 of 22 patients (68%) and CD56 positivity in four patients (18%). CD7 positivity was observed in seven patients (58%) with AML and in eight patients (80%) with ALL. CD56 positivity was observed in three patients (25%) with AML and one patient (10%) with ALL. Lymphadenopathy was present in five patients and associated with hepatosplenomegaly in three patients with ALL. Splenomegaly and hepatomegaly were present in three patients with AML. Central nervous system involvement was seen in one patient with ALL. Complete remission was achieved in nine patients (41%) (five ALL and four AML). Our data showed that CD7 and CD56 positivity at diagnosis associated with low remission rate and biological aggressiveness in a significant proportion of patients. We suggest the evaluation of CD7 and CD56 in all patients with acute leukaemias at the time of diagnosis in view of poor clinical outcome.
  • [ X ]
    Öğe
    Incidence of aplastic anemia in Turkey
    (Pergamon-Elsevier Science Ltd, 1997) Baslar, Z; Aktuglu, G; Bolaman, Z; Büyükkeçeci, F; Gezer, S; Kansu, E; Koçak, R
    The incidence of aplastic anemia among hospitalized adult patients was prospectively determined in this first study in Turkey, New cases of aplastic anemia among patients 14 years and older who were admitted to the study centers were included in a 3 year survey. Seventy-three patients fulfilled the diagnostic criteria, yielding a mean annual incidence rate of 1.14 cases in 10(3) admissions. The male-to-female ratio of the cases (1.6:1) differed from the almost equal ratio of the larger population of Turkey, The median age was 30 years and females were younger at diagnosis. The age distribution of the cases was different from that of the population; showing two incidence peaks in both sexes, The majority of the patients (89%) had severe disease. (C) 1997 Elsevier Science Ltd. All rights reserved.
  • [ X ]
    Öğe
    Meropenem monotherapy for empiric treatment of febrile neutropenic cancer patients
    (Medimond S R L, 2000) Ayyildiz, O; Iskakdogan, A; Bolaman, Z; Müftüoglu, E
    Empirical antibacterial therapy should be administered to all neutropenic cancer patients with fever or clinical evidence of infection even in the absence of fever. A total of fifty cancer patients with 72 neutropenic episodes were enrolled in the study. Twenty-one (29%) episodes had a microbiologically defined infection, 20 (28%) a clinically defined infection and the remaining 31 (43%) had unexplained fever. 72 episodes initially treated with meropenem 1 g i.v. every 8 h. Gram negative pathogens were 11 (52%) predominated over gram positive isolates were 7 (33%). The success rate without adjustment was 29% in gram positive group and 91% in gram negative group. There were no reports of drug-related nausea/ vomiting or seizures. One patient with AML died of gram positive sepsis resistant to treatment. In conclusion,meropenem monotherapy seemed effective and side effects were tolerable for the treatment of febrile neutropenic cancer patients.
  • [ X ]
    Öğe
    Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey
    (Springer, 2004) Ayyildiz, O; Kalkanli, S; Batun, S; Aybak, M; Isikdogan, A; Tiftik, N; Bolaman, Z
    Venous thrombosis (VT) is a common disease, with an annual incidence in the general population of approximately 1 per 1000. The prevalence of genetic risk factors for thrombosis varies greatly in different parts of the world. Prothrombin G20210A (PT G20210A) gene mutation has been recently identified as a common risk factor in venous thrombosis. Sixty-one patients with VT, differing in age and sex, and 340 healthy subjects were consecutively enrolled into our study to determine the prevalence of PT G20210A in VT and in the healthy population of the southeast of Turkey. The mutation was identified with fluorescence resonance energy transfer (FRET) with the LightCycler polymerase chain reaction. The PT G20210A mutation was found to be 6.5% (4/61) in the VT group and 1.2% (4/340) in the healthy group (P = 0.021). Three patients with VT had a heterozygous PT G20210A mutation, and the other patient with VT had both Factor V Leiden and PT G20210A mutations. We showed that this method may be used safely for detection of the PT G20210A gene mutation, and the prevalence of PT G20210A mutation is significantly higher in patients with VT than in the healthy population in the southeast of Turkey.
  • [ X ]
    Öğe
    Treatment of advanced chronic lymphocytic leukemia by fludarabine
    (Medimond S R L, 2000) Ayyildiz, O; Tiftik, N; Bolaman, Z; Müftüoglu, E
    Ten patients with B-cell chronic lymphocytic leukemia (CLL), aged 55-72 years, 9 male and 1 female, were treated with fludarabine. Fludarabine is the most active agent for treatment of CLL. All patients were previously treated with alkylating agent-based regimen. Fludarabine was administered for 5 consecutive days 25 mg/m(2)/d and repeated 4-weekly. The response rate was 40% with 1 complete response and 3 partial responses. However, four patients achieved stable disease and 2 progressed. The median survival for responders was 18 months and for non-responders 8 months. Our patients tolerated the fludarabine treatment extremely well. Myelosupression was seen in eight patients. In a total of 37 treatment courses 5 febrile episodes were registered in 4 patients and successfully treated with empirical antibiotic regimen. In conclusion, fludarabine is effective in CLL patients refractory to first-line chemotherapy.